Aptevo Therapeutics INC 8-K filings

Aptevo Therapeutics announces its 2024 financial results and provides a business update, showcasing promising clinical trial data for mipletamig in AML and ALG.APV-527 in solid tumors.

Aptevo Therapeutics showcases its drug pipeline, including clinical candidates mipletamig and ALG.APV-527, and preclinical candidates, emphasizing their potential in oncology.

Aptevo Therapeutics has entered into a warrant inducement agreement, potentially raising approximately $6.2 million through the exercise of existing warrants.

Aptevo Therapeutics reports that all patients in the first cohort of their RAINIER trial achieved remission within 30 days, including two with complete elimination of cancer cells.

Aptevo Therapeutics has unveiled additional details about its preclinical bispecific antibody, APVO442, designed to precisely target prostate cancer with reduced side effects using its ADAPTIR-FLEX platform.

Aptevo Therapeutics has completed a 1-for-37 reverse stock split, effective December 3, 2024, to consolidate its shares and adjust its stock price.

Aptevo Therapeutics' Senior Director of Protein Engineering, Dr. Peter Pavlik, will chair a session on biand multispecific biologics and present on the company's modular ADAPTIR platform at the upcoming Pep Talk conference in January 2025.

Aptevo Therapeutics is advancing its bispecific antibody pipeline, showcasing positive clinical results and potential for growth in the oncology treatment market.

Aptevo Therapeutics announced that the first patient in its RAINIER trial achieved a 90% reduction in leukemic blasts within 30 days of treatment with mipletamig, supporting the efficacy trend seen in prior studies.

Aptevo Therapeutics announced its third quarter 2024 financial results, highlighting clinical milestones and a $5.75 million capital raise.

Aptevo Therapeutics has extended the expiration date of its shareholder rights agreement to October 31, 2025, and increased the purchase price of preferred shares to $70 per one one-thousandth of a share.

Aptevo Therapeutics stockholders approved a stock issuance and warrant proposal, an amendment to the certificate of incorporation for a potential reverse stock split, and authorization to adjourn the special meeting if needed.

Aptevo Therapeutics has successfully completed a $3.0 million registered direct offering, priced at-the-market under Nasdaq rules, and amended existing warrants to reduce their exercise price.

Aptevo Therapeutics and Alligator Bioscience reported that 60% of evaluable patients achieved stable disease in a Phase 1 trial of ALG.APV-527 for solid tumors.

Aptevo Therapeutics reported its Q2 2024 financial results, highlighted by a 91% clinical benefit rate in its APVO436 trial and a recent $2.75 million capital raise.

Aptevo Therapeutics' stockholders did not approve the company's Amended and Restated Certificate of Incorporation at a special meeting held on August 6, 2024, but approved a stock issuance and warrant proposal and the authorization to adjourn the meeting if needed.

Aptevo Therapeutics has received a notice from Nasdaq regarding its failure to maintain a minimum share price of $1, placing it at risk of delisting.

Aptevo Therapeutics has successfully completed a $2.75 million registered direct offering, priced at-the-market under Nasdaq rules, to fund clinical development and working capital.

Aptevo Therapeutics held its 2024 Annual Meeting of Stockholders, electing two directors, ratifying the appointment of an accounting firm, and approving a stock incentive plan and executive compensation.

Aptevo Therapeutics announced its first quarter 2024 financial results, highlighting progress in clinical programs and a stable disease outcome for a breast cancer patient in the ALG.APV-527 trial.

Aptevo Therapeutics has successfully priced a public offering to raise $4.6 million through the sale of common stock and warrants.

Aptevo Therapeutics and Alligator Bioscience reported positive interim results from a Phase 1 trial of their cancer drug, ALG.APV-527, showing favorable drug exposure and early signs of clinical activity.

Aptevo Therapeutics has completed a 1-for-44 reverse stock split, effective March 5, 2024, to maintain Nasdaq listing compliance.

Aptevo Therapeutics reported its 2023 financial results, highlighted by a net loss of $17.4 million, and provided a business update, including plans to advance its lead candidate APVO436 into a Phase 1b/2 trial.

Aptevo Therapeutics stockholders approved a reverse stock split and the issuance of new warrants at a special meeting on February 5, 2024.